Skip to main content Skip to search Skip to main navigation

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA and PIC/S have published a concept paper announcing a targeted revision of Annex 6 Manufacture of Medicinal Gases of the EU GMP Guide. The last update dates from 2010. The revision aims to reflect current manufacturing practice, technological progress and lessons learned from the COVID-19 pandemic.

Key elements under discussion

The revision will be focused and limited in scope, addressing in particular:

  • Premises requirements
    Reassessment of the applicability of general GMP requirements to closed, pressurised gas manufacturing systems.
  • Technological developments
    Consideration of modern safety features such as gas-specific couplings, elimination of containers without residual pressure valves and adapted valve/residual gas checks to reduce contamination risks.
  • Cylinders with integrated pressure regulator flowmeters
    Clarification of inspection requirements before and after refilling and definition of control frequencies; inclusion of cryogenic containers.
  • Medicinal liquid oxygen supply to hospitals
    Strengthening and clarification of documentation and quality assurance requirements for the filling of the hospital’s tank evaporation units.
  • Batch certification (in addition to Annex 16)
    Assessment of potential specific provisions for medicinal gases, including QP availability and possible remote certification aspects.
  • Qualification of facilities and containers
    Clarification regarding qualification of production plants, mobile/stationary tanks and reusable containers.

Timeline

  • Public consultation until 11 April 2026
  • Draft guideline: November 2026
  • Finalisation: 2027


Quelle:

EMA: Concept paper on revision of the guidelines on Good Manufacturing Practice for medicinal products - Annex 6 Manufacture of Medicinal Gases

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

How do Components like Filling Needles and Laminarisators Affect First Air Integrity?

How do Components like Filling Needles and Laminarisators Affect First Air Integrity?

Here's the answer:
Read more
Smart Strategies for Handling Indirect Product Contact Components

Smart Strategies for Handling Indirect Product Contact Components

Aseptic filling processes: Handling indirect product contact parts in compliance with the revised Annex 1 of the EU GMP Guide.
Read more
Swissmedic: Implementation of New EU GMP Implementing Regulations for Veterinary Medicinal Products

Swissmedic: Implementation of New EU GMP Implementing Regulations for Veterinary Medicinal Products

The new EU Implementing Regulations on GMP requirements for veterinary medicinal products and active substances will not be automatically transposed into the Swiss Medicinal Products Licensing Ordinance (MPLO) on 16 July 2026. Swissmedic has confirmed that, although the structure of the new EU legislation has changed, the underlying GMP requirements remain largely unchanged.
Read more
EU: Annexes 4 and 5 no Longer Included in the EU GMP Guide

EU: Annexes 4 and 5 no Longer Included in the EU GMP Guide

Following the entry into application of Commission Implementing Regulations (EU) 2025/2091 and (EU) 2025/2154 on the principles and guidelines of Good Manufacturing Practice (GMP) for veterinary medicinal products and active substances for veterinary medicinal products on 16 July 2026, the European Commission removed Annexes 4 and 5 from the EU GMP Guide.
Read more
EMA: Revision of Annex 15 Delayed

EMA: Revision of Annex 15 Delayed

In February 2026, the EMA published a concept paper on the revision of Annex 15 "Qualification and Validation" of the EU GMP Guide (we reported previously). The Agency has now released a corrected version containing a significantly revised timetable.
Read more
EU: Updated Q&A on Safety Features for Human Medicinal Products

EU: Updated Q&A on Safety Features for Human Medicinal Products

The European Commission has published Version 22 of its Questions and Answers on Safety Features for Medicinal Products for Human Use.
Read more
Previous
Next